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THE ASSESSMENT OF THE INFLUENCE OF AN
EDUCATIONAL INTERVENTION ON PATIENT
IMPORTANT OUTCOMES INCLUDING HEALTH
RELATED QUALITY OF LIFE (HRQOL) AND
MORTALITY USING A TIME-TO-EVENT
SURVIVAL ANALYSIS IN PATIENTS WITH 
HEART FAILURE
Gwadry-Sridhar F1,Weaver B1, Guyatt G1,Arnold M2
1McMaster University, London, ON, Canada; 2London Health
Sciences Centre, London, ON, Canada
OBJECTIVES: Patients with HF can suffer from poor
HRQoL particularly as their disease progresses. We
wanted to determine whether HRQoL and mortality dif-
ferences existed between patients following an interven-
tion. We deﬁned an event as either death or a drop from
baseline of at least 10 points in the PCS or MCS summary
scales of the SF-36 that was sustained on at least 2 con-
secutive intervals with no recovery prior to study termi-
nation. METHODS: This was an RCT (n = 134) with
HRQoL collection from baseline every 3 months to 1
year. All data collection and outcomes assessment were
done by study personnel who were blinded to patient
treatment allocation. Complete SF-36 data were available
on 114 patients. We did a Cox regression time-to-event
survival analysis adjusting for Arm. RESULTS: Accord-
ing to our deﬁnition of events 14.9% of patients had a
PCS event and 16.7% of patients had an MCS event.
There was no signiﬁcant effect of Arm. CONCLUSIONS:
A 10-point drop in the PCS or MCS can be considered to
be a minimal clinically important difference in patients
with a sustained drop indicating no response to the inter-
vention. The analytic techniques we used expand the
interpretability of HRQoL changes and incorporate 
clinical outcomes.
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WHAT IS THE WILLINGNESS TO PAY FOR
FUTURE HEALTH BENEFITS AMONG
HYPERTENSIVE PATIENTS—A PILOT STUDY IN
POLISH SETTING
Czech M1, Splawiñski J2, Hermanowski T2, Pachocki R1,
Czech M3
1Servier Polska, Warsaw, Poland; 2Drug Institute, Warsaw,
Poland; 3Warsaw University of Technology, Warsaw, Poland
OBJECTIVE: Although there is no ﬁnal agreement on
how willingness to pay (WTP) should be measured, 
it is increasingly used to value future health beneﬁts. 
The objective is to measure the ﬁnancial value of po-
tential health beneﬁts from antihypertensive treatment.
METHODS: The study was carried out in 103 hyperten-
sive patients in 3 centres in Poland. The WTP for theo-
retical antihypertensive agent (drug A) was measured
assuming that it would reduce the risk of ischemic heart
disease and strokes in the future. Patients were able to
choose the treatment or non-treatment option, data
obtained were conﬁdential. Three types of potential ben-
eﬁts from the new healthcare intervention were measured:
patient beneﬁts, insurance/option value and altruistic
value. RESULTS: The average WTP was €14,47 in terms
of drug’s price (patient beneﬁt), €3,16 as an insurance
premium (private beneﬁt) and €1,16 in additional taxes
(societal beneﬁt, all on monthly bases). Differences 
due to the regional level of development (wealth) were
observed. A strong correlation between individual income
and WTP was detected. The correlation between WTP
and a level of education and occupational status is
weaker. CONCLUSION: Patients are willing to pay more
then twice as much as the average price of a drug avail-
able on the market, (if not reimbursed) and 3.7 times the
amount of patient co-payment (if the drug is reimbursed).
Patients are willing to allocate a substantial part of their
income to avoid the complications of hypertension.
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OBJECTIVES: Many prescription drug markets are
inhabited by multiple patented drugs that perform similar
functions at different effectiveness levels without generic
competition. Little is known about the inﬂuence of drug
beneﬁts on drug choice in these markets. This paper
employs a multinomial logit regression to estimate 
the inﬂuence of copayments on demand for statins for
patients diagnosed with coronary heart disease (CHD).
METHODS: Patients selected for inclusion in the study
(N = 36,135) from the MarketScan Commercial Claims
and Encounters database were required to have an ICD-
9 diagnosis of CHD, use one of ﬁve statins (atorvastatin,
ﬂuvastatin, lovastatin, pravastatin, or simvastatin), and
be continuously enrolled in an identiﬁed health plan. To
estimate the inﬂuence of health plan beneﬁts on usage,
the average copayment for each patient’s statin over his
relevant therapy period was calculated relative to pravas-
tatin. Other explanatory variables used to control for
variation in statin choice included demographic factors,
clinical comorbidities, insurance type, and a proxy for
primary CHD prevention. RESULTS: Most patients in
the sample are treated with atorvastatin (N = 13,162) or
simvastatin (N = 12,863). The copayment of the patient’s
statin of choice has a highly signiﬁcant inﬂuence on statin
choice. An increase in the patient’s copayment relative to
the copayment of pravastatin, over the patient’s therapy
period, decreases the likelihood of receiving that statin by
as much as 84% (lovastatin), and as little as 11% (ator-
vastatin). CONCLUSION: Findings suggest that insurers
can inﬂuence a patient’s choice of one drug over another
by varying a patient’s copayment level. Moreover, results
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are consistent with general clinical prescribing patterns
and comparable efﬁcacy of statins. Patients treated with
atorvastatin are least likely to be inﬂuenced by copayment
than patients using other statins.
CARDIOVASULAR DISEASES/DISORDERS—
Healthcare Policy
PCV50
EVALUATION OF NITRATE PRESCRIPTION
PATTERNS AMONG PHYSICIANS FROM
DIFFERENT SPECIALITIES IN ISRAEL
Reuveni H, Preis M, Elhayani A, Lifshitz M, Peled R
Ben Gurion University, Beer Sheva, Israel
OBJECTIVES: Nitrates are the treatment of choice for
angina pectoris. Isosorbide dinitrate (Id) has the same
clinical effect and is less costly than isosorbide mononi-
trate (Im). Id is the recommended treatment of choice for
angina pectoris in Israel and Britain. An early study shows
very low prescription rate of Id versus Im in Israel. This
study characterizes factors affecting nitrate prescription
patterns among specialist doctors in Israel. METHODS:
One hundred nine specialists (cardiologists, internists,
family physicians) were requested to answer an anony-
mous questionnaire about the treatment of choice for a
case of a stable angina patient. Questions included the
following parameters: knowledge regarding effectiveness/
safety/cost, prescription preference, drug promotion
effect, awareness of clinical guidelines. RESULTS:
Twenty-one cardiologists, 29 internists, 39 family physi-
cians were interviewed. Of all doctors only 26.7% stated
that they prescribe dinitrates. 44.4% do not know of any
difference between drugs, and they prescribe mononi-
trates out of habit. Family physicians prescribe dinitrates
eight-fold compared to cardiologists. 62.9% stated the
drug’s price does affect their decision-making. 32% didn’t
receive any guidelines regarding the preferred treatment
for angina pectoris. CONCLUSIONS: Relatively high
awareness to clinical guidelines favoring Isosorbide dini-
trate for treatment of angina is contradictory to the over
prescription of mononitrates. Cardiologists in particular
believe that mononitrates are more effective than dini-
trates. Even physicians who know that there is no differ-
ence between the drugs explain their prescription pattern
is based on clinical experience and out of habit. Aware-
ness to drug prices did not inﬂuence prescription patterns
toward less costly drugs. Most doctors who received
guidelines for treatment of angina didn’t follow their 
recommendations. This study provides the “proof of
concept” that the prescription habits toward mononi-
trates are a waste of scarce resources. Further interven-
tion and cost effectiveness studies are needed to explore
the effects of over prescription of mononitrates.
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POSSIBILITIES OF NEW TECHNOLOGIES
AMONG PATIENTS WITH HYPERTENSION:
FEASIBILITY AND ACCEPTANCE OF AN
EDUCATIVE INTERVENTION THROUGH 
SHORT MESSAGES TO THE PATIENT’S
CELLULAR PHONE
De la Figuera M1, Márquez E2, Ruilope LM3, Figueras M4,
Ylla-Català A4, Balañà M5, Naval J6
1ABS La Mina, Grupo Cumplimiento SEHLELHA, Barcelona,
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Spain; 4Excelent, Barcelona, Spain; 5Excelent Farma, Barcelona,
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OBJECTIVES: A descriptive study of the general interest
in educative programs using new technologies (Internet
for example) and a pilot-trial to demonstrate the feasi-
bility and acceptance of a speciﬁc education pro-
gram based in short messages (SMS) in the cellular 
phone to improve drug compliance have been carried 
out among hypertensive patients (HTP) in Spain.
METHODS: Descriptive data were collected among 
HTP using a self-administered questionnaire. For the
pilot-trial, 30 primary care investigators were randomized
to Control or Intervention Group. Each investigator
recruited four HTP. Availability of a cellular phone was
an inclusion criteria for all patients. Investigators of the
Intervention Group registered their patients in a free SMS
service, after informed consent. Patients in this group
received two short messages per week, addressing issues
related with compliance and health habits. All the
patients in the Intervention group received the messages
during 24 weeks. RESULTS: Two thousand three
hundred sixty-three surveys were collected in the descrip-
tive study. 27% of HTP were Internet users; 56% of the
HTP would visit a web page dedicated to HT, 50% would
consult with their doctors through the Internet, and
43.5% would be willing to receive health messages in
their cellular phones. 120 HTP were willing to participate
in the pilot trial. The mean age was 60,2 in Control
Group and 55,9 in Intervention Group (differences not
signiﬁcant). The messages to the cellular phone were well
accepted by investigators and patients along the sched-
uled period (24 weeks). CONCLUSIONS: The use of
SMSs seems to be a useful tool for educational programs,
especially because cellular phone is an increasingly
popular communications system. As the SMS becomes
more affordable, it would be convenient to explore in
more detail its effectiveness in health outcomes, speciﬁ-
cally regarding compliance.
